Drug Approval | March 19, 2025
Briefs: Zydus, Alkem Laboratories, Alkem Medtech and Relonchem
Alkem Medtech to acquire 100% stake of Bombay Ortho
Alkem Medtech to acquire 100% stake of Bombay Ortho
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
The PIPE offering consists of 36,190,476 units
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
Amgen India investment totals $200 million through 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
